microRNA information: hsa-miR-3200-3p
| Section | ID | link |
|---|---|---|
| Mature name: | hsa-miR-3200-3p | miRbase |
| Accession: | MIMAT0015085 | miRbase |
| Precursor name: | hsa-mir-3200 | miRbase |
| Precursor accession: | MI0014249 | miRbase |
| Symbol: | MIR3200 | HGNC |
| RefSeq ID: | NR_036171 | GenBank |
| Sequence: | CACCUUGCGCUACUCAGGUCUG |
Reported expression in cancers: hsa-miR-3200-3p
| miRNA | cancer | regulation | reporting | PUBMED | method |
|---|
Reported cancer pathway affected by hsa-miR-3200-3p
| miRNA | cancer | pathway | reporting | PUBMED | functional study |
|---|
Reported cancer prognosis affected by hsa-miR-3200-3p
| miRNA | cancer | prognosis | reporting | PUBMED | functional study |
|---|---|---|---|---|---|
| hsa-miR-3200-3p | breast cancer | drug resistance | "Then a panel of four miRNAs miR-451 miR-3200 miR-2 ......" | 27064979 |
Reported gene related to hsa-miR-3200-3p
| miRNA | cancer | gene | reporting | PUBMED |
|---|
Expression profile in cancer corhorts:
Putative target regulations
| miRNA | Gene | Cancer | Interaction | Correlation beta |
|---|---|---|---|---|
hsa-miR-3200-3p | FPR3 | 10 cancers: BLCA; CESC; ESCA; LGG; LIHC; LUAD; LUSC; PAAD; SARC; THCA | MirTarget | TCGA BLCA -0.39; TCGA CESC -0.233; TCGA ESCA -0.151; TCGA LGG -0.726; TCGA LIHC -0.096; TCGA LUAD -0.073; TCGA LUSC -0.314; TCGA PAAD -0.147; TCGA SARC -0.217; TCGA THCA -0.626 |
hsa-miR-3200-3p | RAPGEF5 | 9 cancers: BLCA; CESC; KIRP; LIHC; LUSC; PAAD; SARC; THCA; UCEC | MirTarget | TCGA BLCA -0.118; TCGA CESC -0.164; TCGA KIRP -0.29; TCGA LIHC -0.056; TCGA LUSC -0.086; TCGA PAAD -0.137; TCGA SARC -0.262; TCGA THCA -0.187; TCGA UCEC -0.06 |
hsa-miR-3200-3p | NFIX | 9 cancers: BLCA; CESC; ESCA; KIRP; LGG; LIHC; LUSC; PAAD; UCEC | mirMAP | TCGA BLCA -0.258; TCGA CESC -0.092; TCGA ESCA -0.084; TCGA KIRP -0.194; TCGA LGG -0.116; TCGA LIHC -0.118; TCGA LUSC -0.126; TCGA PAAD -0.148; TCGA UCEC -0.073 |
hsa-miR-3200-3p | IRAK3 | 10 cancers: BLCA; CESC; ESCA; KIRP; LIHC; LUAD; LUSC; PAAD; THCA; UCEC | mirMAP | TCGA BLCA -0.268; TCGA CESC -0.154; TCGA ESCA -0.215; TCGA KIRP -0.21; TCGA LIHC -0.144; TCGA LUAD -0.147; TCGA LUSC -0.337; TCGA PAAD -0.235; TCGA THCA -0.174; TCGA UCEC -0.273 |
hsa-miR-3200-3p | TIMP3 | 9 cancers: BLCA; CESC; ESCA; LIHC; LUAD; LUSC; PAAD; SARC; UCEC | mirMAP | TCGA BLCA -0.27; TCGA CESC -0.185; TCGA ESCA -0.189; TCGA LIHC -0.149; TCGA LUAD -0.103; TCGA LUSC -0.36; TCGA PAAD -0.115; TCGA SARC -0.113; TCGA UCEC -0.36 |
hsa-miR-3200-3p | SNX33 | 12 cancers: BLCA; CESC; ESCA; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; SARC; THCA; UCEC | mirMAP | TCGA BLCA -0.06; TCGA CESC -0.157; TCGA ESCA -0.076; TCGA KIRP -0.076; TCGA LGG -0.079; TCGA LIHC -0.075; TCGA LUAD -0.065; TCGA LUSC -0.089; TCGA PAAD -0.166; TCGA SARC -0.103; TCGA THCA -0.071; TCGA UCEC -0.098 |
hsa-miR-3200-3p | ANTXR2 | 10 cancers: BLCA; ESCA; LGG; LIHC; LUAD; LUSC; PAAD; SARC; THCA; UCEC | miRNATAP | TCGA BLCA -0.304; TCGA ESCA -0.117; TCGA LGG -0.178; TCGA LIHC -0.135; TCGA LUAD -0.144; TCGA LUSC -0.254; TCGA PAAD -0.341; TCGA SARC -0.223; TCGA THCA -0.372; TCGA UCEC -0.42 |
hsa-miR-3200-3p | MBNL2 | 9 cancers: BLCA; CESC; ESCA; KIRP; LIHC; LUAD; LUSC; SARC; UCEC | miRNATAP | TCGA BLCA -0.095; TCGA CESC -0.085; TCGA ESCA -0.114; TCGA KIRP -0.084; TCGA LIHC -0.243; TCGA LUAD -0.077; TCGA LUSC -0.205; TCGA SARC -0.187; TCGA UCEC -0.163 |
Enriched cancer pathways of putative targets